Scholarlink

Purpose of review <p>To examine the evidence and continuing role of strategies for the primary prevention and treatment of obesity in the context of effective obesity pharmacotherapies, through a narrative review.</p> Recent findings <p>Global policies to improve nutritional labelling and reduce sugar-sweetened beverages consumption have been implemented worldwide (&gt; 45 countries) with some success which varies by population and environment. Tailored behavioural interventions are effective and essential to reduce individual risk of progression from preclinical to clinical obesity. Pharmacotherapies are powerful treatment agents for clinical obesity but must consider nutritional and metabolic risks of use and discontinuation. The obesogenic environment continues to undermine individual agency to adopt healthier dietary and physical activity patterns. Population health informatics tools could inform tailored interventions based on real-time risk and contribute to obesity prevention and treatment.</p> Summary <p>Efforts to rebalance investment towards obesity prevention must continue to improve population health and reduce healthcare burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月7日

查看全文
  • María Gómez-Martín,
  • Oliver J. Canfell,
  • Li Kheng Chai,
  • Anna K. Jansson,
  • Robyn Littlewood,
  • Clair Sullivan,
  • Dawn Power,
  • Erin D. Clarke,
  • Louisa Ells,
  • Nienke De Vlieger,
  • Tracy L. Burrows,
  • Clare E. Collins

摘要

Purpose of review

To examine the evidence and continuing role of strategies for the primary prevention and treatment of obesity in the context of effective obesity pharmacotherapies, through a narrative review.

Recent findings

Global policies to improve nutritional labelling and reduce sugar-sweetened beverages consumption have been implemented worldwide (> 45 countries) with some success which varies by population and environment. Tailored behavioural interventions are effective and essential to reduce individual risk of progression from preclinical to clinical obesity. Pharmacotherapies are powerful treatment agents for clinical obesity but must consider nutritional and metabolic risks of use and discontinuation. The obesogenic environment continues to undermine individual agency to adopt healthier dietary and physical activity patterns. Population health informatics tools could inform tailored interventions based on real-time risk and contribute to obesity prevention and treatment.

Summary

Efforts to rebalance investment towards obesity prevention must continue to improve population health and reduce healthcare burden.